BTG’s bioconvertible IVC filter implanted in Arizona patients

This article was originally published here

BTGBTG (LSE: BTG) today announced the first successful implantation of its Sentry bioconvertible inferior vena cava (IVC) filter in patients outside of a clinical trial.

The Sentry device won FDA 510(k) clearance in 2017. London-based BTG acquired the device in September through its purchase of Galway, Ireland–based Novate.

Get the full story on our sister site Medical Design & Outsourcing.

The post BTG’s bioconvertible IVC filter implanted in Arizona patients appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply